15 April 2025NewsEuropeEoin Martyn & Hannah Garvey
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
A new High Court judge will be tasked with the “massive decision” on the plausibility of Bristol Myers Squibb’s key anticoagulant patent, following its appeal over failures in the previous trial, say Eoin Martyn and Hannah Garvey of Taylor Wessing.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.
15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.
13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.